Clinical trial tests systemic cellular rejuvenation: Can epigenetic reprogramming reverse organ ageing without cancer risks?

Indigenous epistemologies often reject the commodification of life extension, framing ageing as a sacred cycle rather than a malfunction. Traditional healing systems, such as those in Māori or Lakota cultures, prioritize environmental harmony and community well-being over individual cellular rejuvenation. The trial’s epigenetic approach—rooted in Western reductionist science—ignores the interconnectedness of mind, body, and ecosystem central to these traditions. Moreover, indigenous knowledge of plant-based senolytics (e.g., *Uncaria tomentosa* or *Panax ginseng*) could offer safer, culturally grounded alternatives to synthetic reprogramming.

The pursuit of cellular ageing reversal echoes 20th-century eugenics and anti-ageing movements, such as the 1930s 'rejuvenation' experiments of Serge Voronoff, which were later discredited. The trial’s reliance on Yamanaka factors (OSKM) mirrors Cold War-era genetic engineering hype, where breakthroughs were often overpromised before safety concerns emerged. Historical precedents, such as the 1990s telomerase gene therapy trials, demonstrate how initial enthusiasm for 'curing' ageing gave way to ethical and practical roadblocks. The current trial risks repeating these patterns without addressing the structural critiques of biomedical anti-ageing research.

Cross-culturally, ageing is often framed as a collective responsibility, as in the Chinese concept of *xiao* (filial piety) or the African *sankofa* principle of learning from the past. In contrast, the trial’s individualistic approach aligns with Western biomedical models that isolate ageing as a cellular defect to be 'fixed,' rather than a societal challenge to be managed. Ayurveda and Traditional Chinese Medicine (TCM) emphasize *prana* or *qi* flow as key to longevity, offering non-invasive pathways to cellular health that contrast with the trial’s high-tech intervention. These perspectives highlight the need for pluralistic, context-sensitive approaches to ageing research.

The trial’s foundation—epigenetic reprogramming via OSKM factors—is grounded in Nobel-winning science but remains experimentally unproven in humans for safety and efficacy. Preclinical studies show that partial reprogramming can reverse ageing markers in mice, but risks of teratoma formation and immune rejection are unresolved. The methodology’s reliance on viral vectors for gene delivery introduces additional oncogenic risks, a concern echoed by the FDA’s cautious stance on gene therapy. Moreover, the trial’s focus on 'reversing' ageing sidesteps the scientific consensus that ageing is a multifactorial process involving telomere attrition, mitochondrial dysfunction, and chronic inflammation.

Artistic and spiritual traditions often depict ageing as a transformative journey, as in the Hindu *Kali Yuga* cycle or the Buddhist concept of *samsara*. Western art, from Shakespeare’s *King Lear* to Picasso’s late works, explores ageing as a source of depth and creativity, challenging the biomedical narrative of decline. The trial’s mechanistic view of cells as 'reprogrammable' machines contrasts with indigenous and mystical traditions that see life as an emergent, sacred process. Creative resistance to anti-ageing narratives can be seen in movements like *age-positive* art, which redefines ageing as a phase of cultural contribution rather than obsolescence.

If successful, the trial could accelerate a biotech-driven longevity economy, exacerbating global health inequities as only the wealthy access 'age-reversal' therapies. Scenario modelling suggests that widespread adoption of cellular rejuvenation could strain pension systems and healthcare infrastructure, while failing to address root causes of age-related diseases like poverty and pollution. Conversely, a failed trial may trigger regulatory backlash, stifling innovation in regenerative medicine. The long-term implications include the potential for 'biological apartheid,' where age becomes a new axis of social stratification, or conversely, a paradigm shift toward preventive, holistic health systems.

Marginalized communities—particularly elderly individuals in low-income countries—are excluded from the trial’s design and benefits, despite bearing the highest burdens of age-related diseases. The trial’s focus on high-tech interventions ignores the lived experiences of those in resource-poor settings, where ageing is shaped by malnutrition, lack of healthcare, and environmental toxins. Indigenous elders, who hold critical knowledge about natural ageing processes, are sidelined in favor of Western scientific authority. Additionally, the trial’s potential to extend lifespans without addressing structural inequalities risks deepening global health disparities, as seen in the unequal distribution of COVID-19 vaccines.